Barrington Research Lowers Henry Schein (NASDAQ:HSIC) Price Target to $78.00

Key Points

• Barrington Research has reduced the target price for Henry Schein's stock from $86.00 to $78.00, indicating a potential upside of 20.31% from the previous close, while maintaining an "outperform" rating.
• Henry Schein recently reported earnings of $1.10 per share, missing analyst expectations of $1.19, despite a year-over-year revenue increase of 3.3% to $3.24 billion.
• Currently, 96.62% of Henry Schein's shares are owned by institutional investors, with several firms increasing their stakes in the company over recent quarters.

Henry Schein (NASDAQ:HSIC - Get Free Report) had its price objective reduced by Barrington Research from $86.00 to $78.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Barrington Research's target price suggests a potential upside of 18.29% from the stock's previous close.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Wells Fargo & Company decreased their target price on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus reiterated a "hold" rating and set a $75.00 target price (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Leerink Partners set a $75.00 price objective on Henry Schein in a report on Monday, July 14th. Finally, Evercore ISI lifted their price objective on Henry Schein from $72.00 to $78.00 and gave the company an "in-line" rating in a report on Wednesday, July 9th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $75.58.

Henry Schein Trading Up 0.1%

NASDAQ HSIC traded up $0.04 on Wednesday, hitting $65.94. 1,931,964 shares of the stock were exchanged, compared to its average volume of 2,156,766. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.75 and a current ratio of 1.41. The stock has a fifty day moving average price of $71.07 and a two-hundred day moving average price of $71.12. The firm has a market capitalization of $8.00 billion, a P/E ratio of 21.27, a P/E/G ratio of 2.17 and a beta of 0.81. Henry Schein has a 52-week low of $60.56 and a 52-week high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.22 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. The firm's quarterly revenue was up 3.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 earnings per share. Research analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Several institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Investment Management Corp VA ADV purchased a new position in Henry Schein in the fourth quarter valued at about $32,000. Rakuten Securities Inc. purchased a new position in Henry Schein in the first quarter valued at about $34,000. ANTIPODES PARTNERS Ltd purchased a new position in Henry Schein in the second quarter valued at about $43,000. Steph & Co. purchased a new stake in shares of Henry Schein during the second quarter worth about $44,000. Finally, CX Institutional grew its stake in shares of Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company's stock worth $48,000 after acquiring an additional 337 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.